Tandem Diabetes Care Inc - Understand $tndm stock

$TNDM Market Cap: $2.12 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$854.4M

TTM

Gross Margin

49.68%

TTM

Net Earnings

-$126.8M

TTM

Current Assets

$752.8M

Q3 2024

Current Liabilities

$259.3M

Q3 2024

Current Ratio

290.36%

Q3 2024

Total Assets

$957.7M

Q3 2024

Total Liabilities

$720.0M

Q3 2024

Book Value

$237.7M

Q3 2024

Cash

$49.04M

Q3 2024

P/E

-16.72

Nov 29, 2024 EST

Free Cash Flow

-$37.37M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$747.7M	$801.2M	$702.8M	$498.8M	$362.3M	$183.9M	$107.6M	$84.25M	$72.85M	$49.72M	$29.01M	$2.475M	$0.00
YoY Change	-6.68%	14.0%	40.89%	37.68%	97.05%	70.88%	27.72%	15.65%	46.51%	71.41%	1072.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$747.7M	$801.2M	$702.8M	$498.8M	$362.3M	$183.9M	$107.6M	$84.25M	$72.85M	$49.72M	$29.01M	$2.475M	$0.00
Cost Of Revenue	$380.0M	$388.2M	$326.6M	$238.3M	$168.1M	$94.04M	$63.51M	$60.66M	$46.27M	$34.47M	$22.84M	$3.823M	$0.00
Gross Profit	$367.7M	$413.0M	$376.2M	$260.5M	$194.2M	$89.82M	$44.09M	$23.59M	$26.58M	$15.25M	$6.167M	-$1.348M	$0.00
Gross Profit Margin	49.17%	51.54%	53.53%	52.23%	53.6%	48.85%	40.98%	28.0%	36.49%	30.67%	21.26%	-54.46%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$352.5M	$335.7M	$261.5M	$204.9M	$165.7M	$105.2M	$86.38M	$82.83M	$78.62M	$75.12M	$44.52M	$22.69M	$16.00M
YoY Change	5.01%	28.36%	27.63%	23.63%	57.5%	21.82%	4.28%	5.36%	4.66%	68.73%	96.21%	41.82%
% of Gross Profit	95.87%	81.28%	69.51%	78.65%	85.34%	117.15%	195.89%	351.11%	295.79%	492.66%	721.94%
Research & Development	$169.7M	$139.1M	$92.05M	$63.57M	$45.20M	$29.23M	$20.66M	$18.81M	$16.96M	$15.79M	$11.08M	$9.009M	$8.300M
YoY Change	21.96%	51.12%	44.8%	40.65%	54.65%	41.46%	9.85%	10.88%	7.42%	42.53%	22.98%	8.54%
% of Gross Profit	46.14%	33.68%	24.47%	24.4%	23.27%	32.54%	46.86%	79.73%	63.82%	103.56%	179.65%
Depreciation & Amortization	$15.72M	$14.33M	$13.85M	$10.45M	$6.072M	$5.821M	$6.866M	$5.489M	$4.829M	$4.389M	$3.167M	$2.032M	$1.280M
YoY Change	9.67%	3.5%	32.48%	72.12%	4.31%	-15.22%	25.09%	13.67%	10.03%	38.59%	55.86%	58.75%
% of Gross Profit	4.27%	3.47%	3.68%	4.01%	3.13%	6.48%	15.57%	23.27%	18.17%	28.78%	51.35%
Operating Expenses	$600.9M	$505.8M	$353.6M	$268.5M	$210.9M	$134.5M	$107.0M	$101.6M	$95.58M	$90.91M	$55.60M	$31.70M	$24.20M
YoY Change	18.8%	43.07%	31.69%	27.28%	56.88%	25.61%	5.31%	6.34%	5.14%	63.51%	75.4%	30.99%
Operating Profit	-$233.2M	-$92.85M	$22.65M	-$7.957M	-$16.72M	-$44.63M	-$62.94M	-$78.05M	-$69.00M	-$75.66M	-$49.43M	-$33.05M	-$24.20M
YoY Change	151.2%	-509.87%	-384.69%	-52.42%	-62.53%	-29.09%	-19.36%	13.11%	-8.8%	53.06%	49.58%	36.56%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$12.98M	-$4.000K	-$6.752M	-$28.30M	-$7.900M	-$72.60M	-$10.10M	-$5.400M	-$3.400M	-$3.800M	-$13.70M	$0.00	-$1.300M
YoY Change	-324500.0%	-99.94%	-76.14%	258.23%	-89.12%	618.81%	87.04%	58.82%	-10.53%	-72.26%		-100.0%
% of Operating Profit			-29.81%
Other Income/Expense, Net	$12.98M	-$4.000K	-$6.752M	-$28.33M	-$7.882M	-$77.93M	-$10.08M	-$5.411M	-$3.404M	-$3.789M	-$13.71M	$33.00K
YoY Change	-324500.0%	-99.94%	-76.16%	259.36%	-89.89%	673.03%	86.31%	58.96%	-10.16%	-72.35%	-41630.3%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$220.3M	-$92.85M	$15.90M	-$36.28M	-$24.60M	-$122.6M	-$73.03M	-$83.46M	-$72.41M	-$79.45M	-$63.14M	-$33.02M	-$25.50M
YoY Change	137.21%	-683.94%	-143.83%	47.46%	-79.92%	67.83%	-12.51%	15.27%	-8.87%	25.84%	91.24%	29.47%
Income Tax	$2.357M	$1.742M	$335.0K	-$1.900M	$149.0K	$51.00K	$8.000K	-$15.00K	$10.00K	$71.00K	$0.00	$0.00	$0.00
% Of Pretax Income			2.11%
Net Earnings	-$222.6M	-$94.59M	$15.57M	-$34.38M	-$24.75M	-$122.6M	-$73.03M	-$83.45M	-$72.42M	-$79.52M	-$63.14M	-$33.02M	-$25.50M
YoY Change	135.33%	-707.7%	-145.27%	38.9%	-79.81%	67.88%	-12.48%	15.23%	-8.94%	25.95%	91.24%	29.47%
Net Earnings / Revenue	-29.77%	-11.81%	2.21%	-6.89%	-6.83%	-66.68%	-67.87%	-99.05%	-99.41%	-159.94%	-217.67%	-1333.94%
Basic Earnings Per Share	-$3.43	-$1.47	$0.25	-$0.56	-$0.42
Diluted Earnings Per Share	-$3.43	-$1.47	$0.24	-$0.56	-$0.42	-$2.549M	-$12.81M	-$26.90M	-$24.97M	-$34.57M	-$27.43M	-$15.71M	-$12.14M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$467.9M	$616.9M	$623.8M	$484.9M	$176.5M	$129.0M	$14.20M	$53.50M	$71.10M	$67.30M	$129.5M	$17.20M	$8.700M
YoY Change	-24.15%	-1.11%	28.65%	174.73%	36.82%	808.45%	-73.46%	-24.75%	5.65%	-48.03%	652.91%	97.7%
Cash & Equivalents	$58.87M	$172.5M	$71.18M	$94.60M	$51.20M	$41.80M	$13.70M	$44.70M	$43.10M	$31.20M	$124.4M	$17.20M	$8.700M
Short-Term Investments	$409.0M	$444.4M	$552.6M	$390.3M	$125.3M	$87.20M	$500.0K	$8.900M	$28.00M	$36.10M	$5.100M	$0.00
Other Short-Term Assets	$16.59M	$7.241M	$8.433M	$6.400M	$4.000M	$3.800M	$2.200M	$6.200M	$4.300M	$3.900M	$3.900M	$2.000M	$900.0K
YoY Change	129.04%	-14.13%	31.77%	60.0%	5.26%	72.73%	-64.52%	44.19%	10.26%	0.0%	95.0%	122.22%
Inventory	$157.9M	$111.1M	$68.55M	$63.70M	$49.10M	$19.90M	$27.00M	$21.20M	$17.50M	$11.90M	$10.30M	$6.300M	$0.00
Prepaid Expenses
Receivables	$105.6M	$114.7M	$110.7M	$82.20M	$46.60M	$35.20M	$20.80M	$11.20M	$14.10M	$7.700M	$5.300M	$2.400M	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$200.0K
Total Short-Term Assets	$748.0M	$850.0M	$811.5M	$637.2M	$276.1M	$187.9M	$64.20M	$92.10M	$107.0M	$90.80M	$149.0M	$27.80M	$9.800M
YoY Change	-12.0%	4.74%	27.36%	130.79%	46.94%	192.68%	-30.29%	-13.93%	17.84%	-39.06%	435.97%	183.67%
Property, Plant & Equipment	$164.3M	$179.2M	$77.89M	$69.80M	$48.50M	$17.20M	$19.60M	$18.40M	$15.50M	$12.60M	$9.900M	$9.000M	$4.200M
YoY Change	-8.29%	130.04%	11.59%	43.92%	181.98%	-12.24%	6.52%	18.71%	23.02%	27.27%	10.0%	114.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$37.56M	$19.00M	$9.092M	$600.0K	$700.0K	$100.0K	$10.10M	$100.0K	$100.0K	$700.0K	$600.0K	$0.00	$0.00
YoY Change	97.64%	109.02%	1415.33%	-14.29%	600.0%	-99.01%	10000.0%	0.0%	-85.71%	16.67%
Total Long-Term Assets	$204.7M	$202.8M	$93.62M	$79.20M	$50.00M	$18.40M	$31.10M	$20.30M	$17.70M	$15.70M	$13.20M	$12.00M	$4.200M
YoY Change	0.92%	116.64%	18.2%	58.4%	171.74%	-40.84%	53.2%	14.69%	12.74%	18.94%	10.0%	185.71%
Total Assets	$952.7M	$1.053B	$905.1M	$716.4M	$326.1M	$206.3M	$95.30M	$112.4M	$124.7M	$106.5M	$162.2M	$39.80M	$14.00M
YoY Change
Accounts Payable	$49.59M	$55.73M	$28.03M	$17.80M	$17.70M	$6.800M	$5.200M	$7.500M	$5.200M	$1.900M	$2.400M	$1.700M	$700.0K
YoY Change	-11.02%	98.81%	57.48%	0.56%	160.29%	30.77%	-30.67%	44.23%	173.68%	-20.83%	41.18%	142.86%
Accrued Expenses	$73.22M	$61.40M	$70.25M	$48.40M	$42.70M	$28.00M	$17.30M	$11.80M	$13.90M	$12.60M	$7.700M	$3.500M	$1.000M
YoY Change	19.25%	-12.61%	45.15%	13.35%	52.5%	61.85%	46.61%	-15.11%	10.32%	63.64%	120.0%	250.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$12.90M
YoY Change												-100.0%
Long-Term Debt Due											$0.00	$4.200M	$0.00
YoY Change											-100.0%
Total Short-Term Liabilities	$195.3M	$165.3M	$131.9M	$103.9M	$99.40M	$66.30M	$36.10M	$31.50M	$26.50M	$18.10M	$14.60M	$17.10M	$16.70M
YoY Change	18.13%	25.36%	26.91%	4.53%	49.92%	83.66%	14.6%	18.87%	46.41%	23.97%	-14.62%	2.4%
Long-Term Debt	$285.0M	$283.2M	$281.5M	$203.0M	$0.00	$0.00	$76.50M	$79.00M	$29.30M	$29.40M	$29.40M	$0.00	$0.00
YoY Change	0.64%	0.63%	38.65%			-100.0%	-3.16%	169.62%	-0.34%	0.0%
Other Long-Term Liabilities	$158.7M	$164.3M	$58.70M	$43.30M	$31.70M	$8.700M	$11.90M	$7.900M	$5.500M	$4.400M	$2.700M	$4.200M	$700.0K
YoY Change	-3.4%	179.92%	35.57%	36.59%	264.37%	-26.89%	50.63%	43.64%	25.0%	62.96%	-35.71%	500.0%
Total Long-Term Liabilities	$443.8M	$447.5M	$340.2M	$246.3M	$31.70M	$8.700M	$88.40M	$86.90M	$34.80M	$33.80M	$32.10M	$4.200M	$700.0K
YoY Change	-0.84%	31.57%	38.11%	676.97%	264.37%	-90.16%	1.73%	149.71%	2.96%	5.3%	664.29%	500.0%
Total Liabilities	$639.0M	$612.8M	$472.0M	$350.1M	$131.1M	$75.00M	$124.5M	$118.3M	$61.30M	$51.90M	$46.70M	$21.20M	$17.30M
YoY Change	4.27%	29.83%	34.83%	167.05%	74.8%	-39.76%	5.24%	92.99%	18.11%	11.13%	120.28%	22.54%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	64.97M shares	64.15M shares	63.00M shares	60.99M shares	58.51M shares
Diluted Shares Outstanding	64.97M shares	64.15M shares	64.35M shares	60.99M shares	58.51M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.12 Billion

About TANDEM DIABETES CARE INC

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,400 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES Axonics, Inc. Enovis CORP CONMED Corp GLAUKOS Corp Inari Medical, Inc. INTEGRA LIFESCIENCES HOLDINGS CORP iRhythm Technologies, Inc. NUVASIVE INC OMNICELL, INC.